211 related articles for article (PubMed ID: 32930787)
41. Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Yamamoto M; Nakao T; Ogawa W; Fukuoka H
Front Endocrinol (Lausanne); 2021; 12():650791. PubMed ID: 34220707
[TBL] [Abstract][Full Text] [Related]
42. Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor.
Lin AL; Donoghue MTA; Wardlaw SL; Yang TJ; Bodei L; Tabar V; Geer EB
J Clin Endocrinol Metab; 2020 Dec; 105(12):3807-20. PubMed ID: 32930787
[TBL] [Abstract][Full Text] [Related]
43. Refractory pituitary adenoma: a novel classification for pituitary tumors.
Dai C; Feng M; Liu X; Ma S; Sun B; Bao X; Yao Y; Deng K; Wang Y; Xing B; Lian W; Zhong D; Ma W; Wang R
Oncotarget; 2016 Dec; 7(50):83657-83668. PubMed ID: 27845901
[TBL] [Abstract][Full Text] [Related]
44. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Hirohata T; Ishii Y; Matsuno A
Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
[TBL] [Abstract][Full Text] [Related]
45. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
46. Aggressive Pituitary Adenomas and Carcinomas.
Ilie MD; Jouanneau E; Raverot G
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):505-515. PubMed ID: 32741485
[TBL] [Abstract][Full Text] [Related]
47. [Aggressive pituitary adenoma and pituitary carcinoma].
Tóth M
Orv Hetil; 2023 Jul; 164(30):1167-1175. PubMed ID: 37516994
[TBL] [Abstract][Full Text] [Related]
48. Pituitary carcinoma: Two case reports and review of literature.
Xu L; Khaddour K; Chen J; Rich KM; Perrin RJ; Campian JL
World J Clin Oncol; 2020 Feb; 11(2):91-102. PubMed ID: 32133278
[TBL] [Abstract][Full Text] [Related]
49. Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.
Kemeny HR; Elsamadicy AA; Farber SH; Champion CD; Lorrey SJ; Chongsathidkiet P; Woroniecka KI; Cui X; Shen SH; Rhodin KE; Tsvankin V; Everitt J; Sanchez-Perez L; Healy P; McLendon RE; Codd PJ; Dunn IF; Fecci PE
Clin Cancer Res; 2020 Mar; 26(5):1141-1151. PubMed ID: 31744830
[TBL] [Abstract][Full Text] [Related]
50. Comparison of Radiographic Approaches to Assess Treatment Response in Pituitary Adenomas: Is RECIST or RANO Good Enough?
Imber BS; Lin AL; Zhang Z; Keshavamurthy KN; Deipolyi AR; Beal K; Cohen MA; Tabar V; DeAngelis LM; Geer EB; Yang TJ; Young RJ
J Endocr Soc; 2019 Sep; 3(9):1693-1706. PubMed ID: 31528829
[TBL] [Abstract][Full Text] [Related]
51. Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience.
Giuffrida G; Ferraù F; Laudicella R; Cotta OR; Messina E; Granata F; Angileri FF; Vento A; Alibrandi A; Baldari S; Cannavò S
Endocr Connect; 2019 May; 8(5):528-535. PubMed ID: 30939449
[TBL] [Abstract][Full Text] [Related]
52.
Hope TA; Calais J; Zhang L; Dieckmann W; Millo C
J Nucl Med; 2019 Sep; 60(9):1266-1269. PubMed ID: 30850506
[TBL] [Abstract][Full Text] [Related]
53. An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.
Alshaikh OM; Asa SL; Mete O; Ezzat S
Endocr Pathol; 2019 Jun; 30(2):118-127. PubMed ID: 30706322
[TBL] [Abstract][Full Text] [Related]
54. Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas.
Zhang D; Way JS; Zhang X; Sergey M; Bergsneider M; Wang MB; Yong WH; Heaney AP
J Clin Endocrinol Metab; 2019 Jun; 104(6):1929-1936. PubMed ID: 30624667
[TBL] [Abstract][Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]